Utility of 30‐day mortality as a quality metric for palliative radiation treatment: A population‐based analysis from Queensland, Australia

Abstract

IntroductionPalliative radiotherapy (PRT) is frequently used to treat symptoms of advanced cancer, however benefits are questionable when life expectancy is limited. The 30‐day mortality rate after PRT is a potential quality indicator, and results from a recent meta‐analysis suggest a benchmark of 16% as an upper limit. In this population‐based study from Queensland, Australia, we examined 30‐day mortality rates following PRT and factors associated with decreased life expectancy.MethodsRetrospective population data from Queensland Oncology Repository was used. Study population data included 22,501 patients diagnosed with an invasive cancer who died from any cause between 2008 and 2017 and had received PRT. Thirty‐day mortality rates were determined from the date of last PRT fraction to date of death. Cox proportional hazards models were used to identify factors independently associated with risk of death within 30 days of PRT.ResultsOverall 30‐day mortality after PRT was 22.2% with decreasing trend in more recent years (P = 0.001). Male (HR = 1.20, 95% CI = 1.13–1.27); receiving 5 or less radiotherapy fractions (HR = 2.97, 95% CI = 2.74–3.22 and HR = 2.17, 95% CI = 2.03–2.32, respectively) and receiving PRT in a private compared to public facility (HR = 1.61, 95% CI = 1.51–1.71) was associated with decreased survival.ConclusionThe 30‐day mortality rate in Queensland following PRT is higher than expected and there is scope to reduce unnecessarily protracted treatment schedules. We encourage other Australian and New Zealand centres to examine and report their own 30‐day mortality rate following PRT and would support collaboration for 30‐day mortality to become a national and international quality metric for radiation oncology centres.